Abbreviations
AASM, American Academy of Sleep Medicine; AMT, anxiety management training ;
ATC, Anatomical erapeutic Chemical classification system; ASAM, American Society
of Addiction Medicine; BZD, benzodiazepine; CBT, cognitive behavioral therapy; CBT-I,
cognitive behavioral therapy for insomnia; CDC, US Centers for Disease Control and
Prevention; CGC, Clinical Guideline Committee; CNS, central nervous system; CPG,
clinical practice guideline; CYP, cytochrome P450; DoD, US Department of Defense; FDA,
US Food and Drug Administration; GABA, gamma-aminobutyric acid; GAD, generalized
anxiety disorder; GRADE, Grading of Recommendations Assessment, Development, and
Evaluation; HPSO, highly potent synthetic opioid; NSDUH, National Survey on Drug
Use and Health; ODT, orally disintegrating tablet; PDMP, prescription drug monitoring
program; PTSD, posttraumatic stress disorder; RID, relative infant dose; SNRI, serotonin-
norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; SUD,
substance use disorder; VA, US Department of Veterans Affairs; XR, extended release
Source
e Joint Clinical Practice Guideline on Benzodiazepine Tapering. Available at:
https://www.asam.org/quality-care/clinical-guidelines/benzodiazepine-tapering.
is clinical practice guideline has been endorsed by the American Academy of Neurolog y,
the American Academy of Physician Associates, the American Association of Nurse
Practitioners, the American Association of Psychiatric Pharmacists, the American College
of Medical Toxicolog y, the American College of Obstetricians and Gynecolog y, the
American Geriatrics Society, and the American Society of Addiction Medicine.
Guideline Committee Members
Emily Brunner, MD, DFASAM (Chair); Chwen-Yuen A. Chen, MD, FACP, FASAM;
Tracy Klein, PhD, FNP, ARNP, FAANP, FRE, FAAN; Donovan Maust, MD, MS;
Maryann Mazer-Amirshahi, PharmD, MD, PhD, MPH, FACMT, FASAM; Marcia
Mecca, MD; Deanna Najera, MPAS, MS, PA-C, DFAAPA; Chinyere Ogbonna, MD,
MPH; Kiran F. Rajneesh, MD, MS, FAAN; Elizabeth Roll, MD; Amy E. Sanders,
MD, MS, MPhil, FAAN; Brett Snodgrass, DNP, FNP-C, ACHPN, FAANP; Amy
VandenBerg, PharmD, BCPP; Tricia Wright, MD, MS, FACOG, DFASAM
Disclaimer
is resource is for informational purposes only, intended as a quick-reference tool based on the
cited source guideline(s), and should not be used as a substitute for the independent professional
judgment of healthcare providers. Practice guidelines are unable to account for every individual
variation among patients or take the place of clinician judgment, and the ultimate decision
concerning the propriety of any course of conduct must be made by healthcare providers aer
consideration of each individual patient situation. Guideline Central does not endorse any specific
guideline(s) or guideline recommendations and has not independently verified the accuracy
hereof. Any use of this resource or any other Guideline Central resources is strictly voluntary.
1258 Upsala Rd
Sanford, FL 32771
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2025 All rights reserved
ASAMBEN02253
